Cardiology – Page 3

Exploring the Impact of Reduced Left Ventricular Function on Outcomes After PCI in Chronic Kidney Disease Patients

By MedXY 09/27/2025

Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall major cardiovascular events.

Cardiology Clinical Updates General Surgery Pathology & Lab Medicine Specialties

Circulating Trimethylamine N-Oxide: A Novel Biomarker for Predicting Abdominal Aortic Aneurysm Progression and Surgical Risk

By MedXY 09/27/2025

Elevated plasma TMAO levels are associated with higher risk of abdominal aortic aneurysm development, rapid aneurysm growth, and need for surgical repair, providing a promising tool for risk stratification and personalized surveillance.

AI Cardiology Specialties

Harnessing Artificial Intelligence for Enhanced Prediction of Complete Heart Block Risk via Electrocardiography

By MedXY 09/27/2025

AIRE-CHB, a novel AI-enhanced ECG model, significantly improves prediction of incident complete heart block, outperforming traditional bifascicular block assessment and offering promising clinical utility in risk stratification and management.

Cardiology news

Long-Term Survival Outcomes After Initial Stress Testing Versus Coronary CTA in Suspected CAD: Insights from the PROMISE Trial

By MedXY 09/27/2025

The PROMISE trial's 10-year follow-up shows no difference in all-cause or cardiovascular mortality between initial functional stress testing and anatomic coronary CTA in symptomatic patients with suspected coronary artery disease.

Cardiology

Sustained Benefits of Physiology-Guided Complete Revascularization in Elderly Myocardial Infarction Patients: Insights from the FIRE Trial Three-Year Follow-Up

By MedXY 09/27/2025

The FIRE randomized clinical trial demonstrates that physiology-guided complete revascularization in patients aged 75 and older with myocardial infarction and multivessel disease maintains significant reductions in death, MI, stroke, and heart failure hospitalizations over a three-year follow-up, outperforming culprit-only treatment.

Cardiology Public Health Specialties

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence

By MedXY 09/27/2025

This review synthesizes evidence on high-dose versus standard-dose influenza vaccines for cardiovascular outcomes in older adults, focusing on the large DANFLU-2 trial and complementary studies, highlighting modest cardiovascular benefits and implications for clinical practice.

Cardiology Nephrology

Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial

By MedXY 09/27/2025

This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise for those with chronic kidney disease.

Cardiology news Specialties

High Prevalence and Clinical Impact of Sleep Apnea in Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort Study

By MedXY 09/27/2025

Sleep disordered breathing affects over half of patients with hypertrophic cardiomyopathy, correlating with worsening myocardial remodeling, diastolic dysfunction, and subclinical myocardial injury, underscoring the need for clinical trials on intervention.

Cardiology Diabetes & Endocrinology Specialties

Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Patients with Heart Failure: Prevalence, Genetics, and Clinical Implications

By MedXY 09/27/2025

A prospective study reveals transthyretin cardiac amyloidosis (ATTR-CA) affects a significant proportion of older Black patients with heart failure, especially men over 75, with nearly half linked to the V142I genetic variant. Hispanic prevalence is lower but still notable.

Cardiology Clinical Updates news Radiology Specialties

Advancing Noninvasive Imaging in Assessing Hemodynamic Significance of Right Coronary Artery Anomalies

By MedXY 09/27/2025

This article reviews a prospective study evaluating noninvasive anatomical and functional imaging methods to determine hemodynamic significance in right anomalous aortic origin of a coronary artery (R-AAOCA), proposing a stepwise diagnostic approach to reduce invasive testing.

Cardiology news Radiology Specialties

Linking Retinal Microvasculature to Silent Coronary Atherosclerosis: Insights from Optical Coherence Tomography Angiography

By MedXY 09/27/2025

Reduced retinal parafoveal vascular density measured by OCTA independently correlates with subclinical coronary atherosclerosis, revealing a novel noninvasive biomarker for cardiovascular risk assessment beyond traditional factors.

Cardiology Clinical Updates Neurology news

Electrophysiological Study Surpasses ECG in Predicting Life-Threatening Conduction Delays in Myotonic Dystrophy Type 1

By MedXY 09/27/2025

In patients with myotonic dystrophy type 1 (DM1), electrophysiological study (EPS) using the His-ventricular (HV) interval is superior to electrocardiogram (ECG) in predicting major bradyarrhythmic events, suggesting enhanced risk stratification with EPS-guided thresholds.

Cardiology Clinical Updates news

Rising Trends into Transcatheter Aortic Valve Reinterventions: Redo TAVR and Explant Procedures from 2012 to 2024

By MedXY 09/27/2025

This article reviews increasing volumes and incidence of transcatheter aortic valve replacement (TAVR) reinterventions, analyzing procedural trends of redo TAVR and TAVR explant over the past decade, emphasizing implications for clinical practice and future strategies.

Cardiology Clinical Updates news

Systolic Blood Pressure as a Key Modifier of Survival Benefit from Microaxial Flow Pump Therapy in Infarct-Related Cardiogenic Shock: Insights from the DanGer Shock Trial

By MedXY 09/27/2025

This post hoc analysis of the DanGer Shock trial reveals that low systolic blood pressure at treatment initiation markedly enhances survival benefit from microaxial flow pump support in infarct-related cardiogenic shock.

Cardiology Internal Medicine

Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials

By MedXY 09/26/2025

Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effective as full dose but lowers bleeding risk.

Cardiology Clinical Updates Internal Medicine news

Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors

By MedXY 09/26/2025

A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.

Cardiology Clinical Updates news

Reevaluating Mortality Risks: The Paradox of Low Apolipoprotein B and LDL-Cholesterol Levels in Cardiovascular Health

By MedXY 09/24/2025

This study finds an unexpected association between low levels of apolipoprotein B and LDL-cholesterol with increased all-cause and cardiovascular mortality, highlighting the complex role of lipid markers in mortality risk assessment.

Cardiology Clinical Updates

Evaluating Aspirin-Free Therapy Versus Dual Antiplatelet Treatment Post-Coronary Stenting: Insights from the STOPDAPT-3 Trial

By MedXY 09/23/2025

The STOPDAPT-3 randomized trial compared aspirin-free low-dose prasugrel monotherapy with standard dual antiplatelet therapy, revealing noninferior cardiovascular outcomes but no reduction in major bleeding after PCI, with signals of increased coronary events in the aspirin-free group.

Cardiology Clinical Updates news

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up

By MedXY 09/22/2025

The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.

Cardiology Clinical Updates news Specialties

Aspirin-Free Strategy in High Bleeding Risk PCI Patients: Insights from STOPDAPT-3 Subgroup Analysis

By MedXY 09/22/2025

In high bleeding risk patients undergoing PCI, aspirin-free prasugrel monotherapy fails to reduce major bleeding and shows increased myocardial infarction risk in ACS but not non-ACS patients, suggesting selective use post-PCI.